Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 6 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
12 Jan 2020
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.

JAK inhibitors may be used alternatively to treat ulcerative colitis

27 Oct 2019

A new class of orally administered drugs has been included in the armamentarium of treatment for ulcerative colitis (UC), according to a recent study, which reports the effectiveness of Janus kinase (JAK) inhibitors, particularly tofacitinib.

“However, more studies are needed to ascertain the safety of tofacitinib in the long term and whether other compounds of this class may be equally effective,” the authors said.

An extensive literature search was conducted to identify studies examining the effects of JAK inhibitors for the treatment of patients with UC.

Tofacitinib, which was recently approved in Europe for the treatment of moderate-to-severe UC, was the more extensively studied drug in this setting.

Evidence suggested the effectiveness of this drug in terms of achieving clinical and endoscopic remission in UC patients who were unresponsive to other treatments, even in those previously treated with biologic therapies. Tofacitinib was also found to significantly improve the quality of life of these patients.

In addition, still a few data were available for the treatment of UC using other JAK inhibitors.

UC is commonly treated with aminosalicylates, corticosteroids and immunosuppressants, as well as biologic drugs when the former therapies are ineffective. However, primary or secondary loss of response occurs in a substantial portion of patients undergoing treatment with biologic agents, according to the authors.

“Thus, new therapeutic options are be[ing] actively explored; among these, there is interest in JAK inhibitors, small molecules that can be administered orally,” they added.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 6 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
12 Jan 2020
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.